AMY TRA: Open Payments
NPI 1043875370 · SARASOTA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,804 in 210 payments from 21 companies in 2025. Trend: 2023 $2,650 · 2024 $3,143 · 2025 $4,804
Food & beverage: $4,727Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 56 | $1,144 |
| Madrigal Pharmaceuticals | 12 | $416 |
| QOL Medical, LLC | 13 | $398 |
| GENZYME CORPORATION | 13 | $376 |
| Janssen Biotech, Inc. | 18 | $356 |
| PFIZER INC. | 14 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $343 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $218 |
| Ardelyx, Inc. | 11 | $192 |
| Lilly USA, LLC | 11 | $170 |
Products named: DUPIXENT, RINVOQ, REZDIFFRA, Sucraid, TREMFYA, LINZESS, ENTYVIO, SKYRIZI.
Industry payments across FL — which companies pay providers there.
